Sopharma AD (WSE:SPH)

Poland · Delayed Price · Currency is PLN

8.04

0.00 (0.00%)

At close: Feb 27, 2026

94.53% (1Y)

Market Cap	4.05B
Revenue (ttm)	5.47B
Net Income (ttm)	270.79M
Shares Out	n/a
EPS (ttm)	0.97
PE Ratio	14.97
Forward PE	n/a
Dividend	0.36 (4.49%)
Ex-Dividend Date	Dec 18, 2025

Volume	119
Average Volume	1,284
Open	8.04
Previous Close	8.04
Day's Range	8.04 - 8.04
52-Week Range	4.00 - 16.00
Beta	0.05
RSI	46.51
Earnings Date	Jan 30, 2026

About Sopharma AD

Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral nervous system; Methylprednisolon for severe allergies and life-threatening conditions; Vitamin C; Valeriana to reduce the stress; and medical devices... [Read more]

Industry Medical Distribution

Sector Healthcare

Founded 1933

Employees 5,905

Stock Exchange Warsaw Stock Exchange

Ticker Symbol SPH

Full Company Profile

Financial Performance

In 2024, Sopharma AD's revenue was 2.14 billion, an increase of 13.27% compared to the previous year's 1.89 billion. Earnings were 77.85 million, a decrease of -18.89%.

Financial numbers in BGN Financial Statements

News

There is no news available yet.